Cellular Targets for Treatment of Retroviral Infection
AssigneeFox Chase Cancer Center
InventorsRene Daniel, Anna Marie Skalka, Gary D. Kao, Giuseppe Nunnari, Roger J. Pomerantz
Life of this patent
Estimating the term…
Abstract
Cellular targets for anti-retroviral drug development are disclosed. The cellular targets comprise ATR kinase and its relevant substrates, based on the identification of the ATR kinase as required for the final step of retroviral DNA integration. Assays for identifying modulators of retroviral integration via the ATR kinase pathway are disclosed, as well as modulators identified by such assays. Pharmaceutical preparations and methods of their use in treating retroviral infection are also disclosed.
Claims9
1-7. (canceled)
A method of interfering with retroviral replication in a host cell infected with the retrovirus, comprising inhibiting an constituent of the host cell needed to repair nucleic acids during retroviral DNA integration into the host cell genome, wherein the constituent is ATR kinase or a downstream target of ATR kinase.
15-25. (canceled)
Dependencies are inferred from the claim text.